Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients

M. Thaha, Widodo, W. Pranawa, M. Yogiantoro, Yasu Tomino

Research output: Contribution to journalArticlepeer-review

33 Citations (Scopus)

Abstract

Aim: Cardiovascular disease is the main cause of mortality in chronic kidney disease patients. Moreover, uremic patients are in a pro-oxidant state and show an increase in asymmetric dimethylarginine (ADMA) levels due to inhibition of the enzyme dimethylarginine dimethylaminohydrolase (DDAH). Asymmetric dimethylarginine per se seems responsible for a 52% increase in the risk of death and for a 34% increase in the risk of cardiovascular events in dialysis patients. Nacetylcysteine (NAC) is a thiol molecule that has direct and indirect antioxidant effects which decrease reactive oxidant species and increase the bioavailability of the DDAH enzyme. The aim of the current study was to determine the effect of intravenous NAC on plasma ADMA level when administered during hemodialysis in end-stage renal disease (ESRD) patients. Materials and methods: 40 patients with ESRD were randomized to receive a 4-hour intravenous infusion of NAC or placebo during a 4-hour hemodialysis session. There were 3 diabetic patients (15%) in the treatment group and 6 patients in the control group. Plasma ADMA levels were measured before and immediately after hemodialysis. Hemodynamic parameters, including pulse pressure, were also measured. The paired t-test was used to compare the difference of ADMA levels before and after hemodialysis in each group, while the independent t-test was used to compare the difference of ADMA levels between the groups. Results: Compared with the pre-dialysis condition, there was a decrease of ADMA level in the control group (1.1253 ± 0.1797 μM to 0.8676 ± 0.1449 μM) (p < 0.001), and in the NAC group (1.1522 ± 0.1737 μM to 0.7844 ± 0.1586 μM) (p < 0.001). Compared with hemodialysis alone, NAC had a greater lowering effect on the ADMA level (21.3 vs. 31.9%, p < 0.05). Conclusion: N-acetylcysteine (NAC) administered intravenously during hemodialysis reduced asymmetric dimethylarginine (ADMA) levels more than hemodialysis alone. significantly.

Original languageEnglish
Pages (from-to)24-32
Number of pages9
JournalClinical Nephrology
Volume69
Issue number1
DOIs
Publication statusPublished - Jan 2008

Keywords

  • Asymmetric dimethylarginine
  • End-stage renal disease
  • Hemodialysis
  • N-acetylcysteine
  • Reactive oxidant species

Fingerprint

Dive into the research topics of 'Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients'. Together they form a unique fingerprint.

Cite this